Jane Street Group, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Jane Street Group, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $10.5 Million - $11.5 Million	269,948 New	269,948 $11 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $4.3 Million - $9 Million	212,098 Added 513.23%	253,424 $10.7 Million
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $1.9 Million - $3 Million	-93,864 Reduced 69.43%	41,326 $902,000
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $2.2 Million - $3.26 Million	92,234 Added 214.72%	135,190 $4.3 Million
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $762,986 - $1.18 Million	33,435 Added 351.17%	42,956 $1.05 Million
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $241,357 - $304,291	9,521 New	9,521 $300,000
Q2 2022 Aug 16, 2022	SELL	$20.62 - $37.15 $483,209 - $870,573	-23,434 Closed	0 $0
Q1 2022 May 17, 2022	SELL	$23.5 - $35.38 $20,797 - $31,311	-885 Reduced 3.64%	23,434 $820,000
Q4 2021 Feb 15, 2022	SELL	$29.21 - $44.64 $39,229 - $59,951	-1,343 Reduced 5.23%	24,319 $788,000
Q3 2021 Nov 16, 2021	SELL	$21.26 - $38.85 $644,879 - $1.18 Million	-30,333 Reduced 54.17%	25,662 $757,000
Q2 2021 Aug 16, 2021	BUY	$12.56 - $29.69 $703,297 - $1.66 Million	55,995 New	55,995 $1.44 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.